This CPB has been revised to state that emicizumab-kxwh (Hemlibra) is considered medically necessary for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in members with hemophilia A with or without the presence of factor VIII inhibitors. (Previously Hemlibra was only considered medically necessary in persons with inhibitors.) This CPB has been revised to state that factor X (Coagadex) is considered medically necessary for: (i) persons with hereditary Factor X deficiency, regardless of age (previously was approved in persons aged 12 years and above); (ii) perioperative management of bleeding in patients with moderate hereditary Factor X deficiency; and (iii) routine prophylaxis to reduce the frequency of bleeding episodes.